Scorpius Holdings, Inc., a contract development and manufacturing organization (CDMO), has announced its engagement of Alliance Global Partners (A.G.P.) to evaluate potential strategic alternatives. The move aligns with the company’s objective to strengthen its market position and identify opportunities for long-term growth
Scorpius Holdings, Inc. , a contract development and manufacturing organisation (CDMO), has partnered with KaloCyte, a pre-clinical biotech therapeutic startup company. Scorpius will enhance manufacturing efficiencies for KaloCyte’s lead candidate, ErythroMer, a dried artificial red blood cell addressing life-threatening blood
Scorpius Holdings, Inc. (NYSE American: SCPX) has announced the launch of a new business unit, Scorpius Ventures, which will help emerging biotech companies onshore the production of biologics. This initiative is designed to ease financial constraints for biotech firms by
Scorpius Holdings, Inc., an integrated contract development and manufacturing organisation (CDMO), has announced a strategic partnership with Celltheon Corporation to enhance cell line development services for clients. The collaboration leverages Celltheon’s proprietary GOLDILOCKS platform to provide a transposase-based cell line
Scorpius Holdings, Inc., an integrated contract development and manufacturing organization (CDMO) has announced a strategic partnership with a U.S.-based biotech company to expand its biomanufacturing capabilities. As part of this agreement, the biotech firm will transfer a research cell bank
